The investigational once-daily single-tablet regimen of Truvada/TMC278 contains 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (as fumarate), both nucleoside reverse transcriptase inhibitors, and 25 mg of rilpivirine (as hydrochloride), a non-nucleoside reverse transcriptase inhibitor
com) under the titles, "RDEA806, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor
, Shows Positive Outcome in Treatment of Naove HIV Patients," and "Resistance to RDEA806 Requires Multiple Mutations Which Have Limited Cross-Resistance to Other NNRTI's," respectively.
RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor
(NNRTI) for the potential treatment of HIV infection.
Four-hundred and forty-seven HIV-1 infected patients have received combination therapy with Emtriva and Viread with either a non-nucleoside reverse transcriptase inhibitor
(Study 934) or protease inhibitor for 48 weeks in clinical studies.
In the United States and the European Union, Truvada is indicated in combination with other antiretroviral agents (such as non-nucleoside reverse transcriptase inhibitors
or protease inhibitors) for the treatment of HIV-1 infection in adults.
Emivirine (Coactinon), a non-nucleoside reverse transcriptase inhibitor
(NNRTI) in Phase III clinical development, was studied for pharmacokinetic interactions with zidovudine/lamivudine or zidovudine/indinavir.
amp; HUDDINGE, Sweden -- Bristol-Myers Squibb Company (NYSE:BMY) and Medivir AB (STO:MVIRb) today announced a worldwide collaboration to develop and commercialize MIV-170, a preclinical non-nucleoside reverse transcriptase inhibitor
, or NNRTI, intended for the treatment of HIV-1 infection in adults as part of an antiretroviral drug regimen.
Masood, Anti-HIV cytotoxicity enzyme inhibition and molecular docking studies of quinoline based chalcones as potential non-nucleoside reverse transcriptase inhibitors
Its products include protease inhibitors, levetiracetam assay, topiramate assay, non-nucleoside reverse transcriptase inhibitors
, gabapentin assay, lamotrigine assay, zonisamide assay, methotrexate assay, thyroxine assay, and entry inhibitor.
Both are non-nucleoside reverse transcriptase inhibitors
, which block HIV viral replication.
The group conducted a study, published recently in the New England Journal of Medicine, that investigated the association of cumulative exposure to protease inhibitors and non-nucleoside reverse transcriptase inhibitors
with the risk of myocardial infarction.
nucleoside analogue reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors
(NNRTIs), RNA polymerase inhibitors, integrase inhibitors.